Baker Danial E, Demaris Kendra
Hosp Pharm. 2016 Nov;51(10):847-854. doi: 10.1310/hpj5110-847.
Each month, subscribers to receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of publishes selected reviews in this column. For more information about , contact Wolters Kluwer customer service at 866-397-3433. The November 2016 monograph topics are apaziquone, crisaborole, irinotecan liposome, plecanatide, and telotristat. The Safety MUE is on methylnaltrexone PO.
每月，订阅者会收到5至6篇关于新发布或处于3期临床试验后期的药物的详尽专题论文。这些专题论文面向药学与治疗学委员会。订阅者还会每月收到1页的关于对议程以及药学/护理在职培训有用的药物的总结专题论文。每月还会提供一份全面的目标药物利用评估/用药评估（DUE/MUE）。订阅后，专题论文可供订阅者在线获取。专题论文可定制以满足机构的需求。通过合作，出版方会在本专栏发表精选评论。如需了解更多关于……的信息，请致电866 - 397 - 3433联系威科集团客户服务部。2016年11月的专题论文主题包括阿帕西醌、克立硼罗、伊立替康脂质体、普卡那肽和替洛曲汀。安全性MUE针对口服甲基纳曲酮。
